Beyond attenuation: a translational review of curative-intent pharmacological targets in idiopathic pulmonary fibrosis

Idiopathic Pulmonary Fibrosis (IPF) is a progressive, fatal lung disease with a median survival of 3–5 years, driven by a profound unmet medical need. The current standard-of-care agents, pirfenidone and nintedanib, merely slow disease progression and are burdened by significant toxicity. This review synthesizes the basic, clinical, and translational evolution of novel pharmacological approaches for IPF, analyzing the critical lessons from recent high-profile clinical trial failures and successes. This review followed a narrative, analytical methodology, examining key Phase 2 and 3 clinical trials to identify a “failure-to-refinement” trajectory in drug development. Analysis reveals that targeting broad-spectrum enzymes (e.g., autotaxin via ziritaxestat) or downstream effectors (e.g., Connective Tissue Growth Factor (CTGF) via pamrevlumab) has failed, likely due to mechanistic redundancy or insufficient target engagement. In contrast, highly specific, next-generation inhibitors targeting upstream signal initiation points such as the lysophosphatidic acid receptor 1 (LPAR1) (admilparant) and local αv β 6 integrin-mediated activation of transforming growth factor-beta (TGF-β) (bexotegrast) have yielded promising Phase 2 data, demonstrating a sophisticated translational learning loop. Furthermore, the geroscience approach targeting cellular senescence (dasatinib/quercetin) has introduced a controversial new paradigm, while the recent approval of nerandomilast (a phosphodiesterase 4B (PDE4B) inhibitor) establishes a new therapeutic class. The IPF pipeline has matured, moving from broad attenuation toward specific, mechanism-based inhibition. This shift, informed by interpreting trial failures, is guiding the development of therapies toward disease modification and combination strategies, offering a tangible path toward curative-intent treatments.